ASA Opposes Proposed FDA Changes to Opioid Labels
PROP has petitioned the FDA to consider changes for non-cancer pain, including striking the term "moderate" from the indication, adding a maximum daily dose of 100mg of morphine and adding a maximum duration of 90 days for continuous use.
However, ASA representatives argue these limits on daily doses may restrict physicians from prescribing what they think is necessary to treat pain. In formal communication with the FDA, Daniel Carr, MD, a member of the ASA Committee on Pain Medicine, called the changes "not scientifically founded" or practical.
Dr. Carr also pointed out, among other issues, that it is often difficult to separate cancer versus non-cancer pain since cancer treatments often lead to chronic pain. The recommendations would make anesthesiologists' difficult work even more difficult, he said.
More Articles on Anesthesia:
5 Points to Consider Before Merging an Anesthesia Practice
Anesthesiologist Dr. Shawn Crook Joins Bothwell Regional Health Center
Hamilton Medical Issues Alert for Anesthesia Ventilator Software Problems
© Copyright ASC COMMUNICATIONS 2016. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- LifeBond's surgical sealant kit receives FDA IDE approval: 4 things to know
- What is the evidence for using FMT to treat IBD? 5 insights
- Saint Francis Healthcare System adds Dr. Jason Conway: 3 observations
- Premise Health receives AAAHC accreditation for health centers: 5 key notes
- Humana to leave most ACA exchanges after losing $1B: 5 notes